Aryl hydrocarbon receptor and experimental autoimmune arthritis

被引:49
作者
Nam Trung Nguyen [1 ,2 ]
Nakahama, Taisuke [1 ,3 ]
Kishimoto, Tadamitsu [1 ]
机构
[1] Osaka Univ, WPI Immunol Frontier Res Ctr, Lab Immune Regulat, Suita, Osaka 5650871, Japan
[2] Vietnam Acad Sci & Technol, Inst Biotechnol, Natl Key Lab Gene Technol, Hanoi, Vietnam
[3] Osaka Univ, Lab RNA Funct, Grad Sch Med, Suita, Osaka 5650871, Japan
基金
日本学术振兴会;
关键词
Dioxin receptor; Rheumatoid arthritis; JUVENILE IDIOPATHIC ARTHRITIS; COLLAGEN-INDUCED ARTHRITIS; ANTITUMOR NECROSIS FACTOR; REGULATORY T-CELLS; E3 UBIQUITIN LIGASE; PHASE-III TRIAL; RHEUMATOID-ARTHRITIS; INTERLEUKIN-6; RECEPTOR; IL-6; CONCOMITANT METHOTREXATE;
D O I
10.1007/s00281-013-0392-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aryl hydrocarbon receptor (Ahr) is thought to be a crucial factor that regulates immune responses. Many Ahr-mediated immune regulatory mechanisms have been discovered, which will likely enhance our understanding of the molecular pathogenesis of autoimmune inflammation including rheumatoid arthritis (RA). RA is a systemic inflammatory disease that affects approximately 1 % of the population and is characterized by chronic inflammation of the synovium and subsequent joint destruction. Recent findings showed that Ahr plays critical roles in the development of Th17 cells, which are key effector T cells in a variety of human autoimmune diseases including RA. Consistent with these findings, our previous study demonstrated that Ahr in T cells is important for the development of collagen-induced arthritis, a widely used murine model of human RA, possibly via the induction of Th17 cells. In addition, Ahr is an attractive molecule because tobacco smoke is a well-known environmental risk factor for RA development and Ahr agonists, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methyl cholanthrene, and benzo[a]pyrene, are major toxic components in cigarettes. This review summarizes recent findings on Ahr functions in immune cells in the context of RA pathogenesis during stimulation with smoking-derived ligands. We also discuss the potential link between Ahr and novel factors, such as microRNAs, in the development of RA, thereby providing further mechanistic insight into this autoimmune disorder.
引用
收藏
页码:637 / 644
页数:8
相关论文
共 90 条
  • [31] IL-6: Regulator of Treg/Th17 balance
    Kimura, Akihiro
    Kishimoto, Tadamitsu
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (07) : 1830 - 1835
  • [32] Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses
    Kimura, Akihiro
    Naka, Tetsuji
    Nakahama, Taisuke
    Chinen, Ichino
    Masuda, Kazuya
    Nohara, Keiko
    Fujii-Kuriyama, Yoshiaki
    Kishimoto, Tadamitsu
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (09) : 2027 - 2035
  • [33] Interleukin-6: From basic science to medicine - 40 years in immunology
    Kishimoto, T
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 : 1 - 21
  • [34] Interleukin-6: discovery of a pleiotropic cytokine
    Kishimoto, Tadamitsu
    [J]. ARTHRITIS RESEARCH & THERAPY, 2006, 8 (Suppl 2)
  • [35] Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway
    Kitamura, Masanori
    Kasai, Ayumi
    [J]. CANCER LETTERS, 2007, 252 (02) : 184 - 194
  • [36] Rheumatoid arthritis
    Klareskog, Lars
    Catrina, Anca Irinel
    Paget, Stephen
    [J]. LANCET, 2009, 373 (9664) : 659 - 672
  • [37] A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritis
    Kobayashi, S.
    Okamoto, H.
    Iwamoto, T.
    Toyama, Y.
    Tomatsu, T.
    Yamanaka, H.
    Momohara, S.
    [J]. RHEUMATOLOGY, 2008, 47 (09) : 1317 - 1322
  • [38] The roles of polyphenols in cancer chemoprevention
    Lee, Ki Won
    Lee, Hyong Joo
    [J]. BIOFACTORS, 2006, 26 (02) : 105 - 121
  • [39] Th17 cytokines and arthritis
    Lubberts, Erik
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2010, 32 (01) : 43 - 53
  • [40] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial
    Maini, R
    St Clair, EW
    Breedveld, F
    Furst, D
    Kalden, J
    Weisman, M
    Smolen, J
    Emery, P
    Harriman, G
    Feldmann, M
    Lipsky, P
    [J]. LANCET, 1999, 354 (9194) : 1932 - 1939